Sage Therapeutics Inc (SAGE)
7.29
+0.12
(+1.67%)
USD |
NASDAQ |
Sep 27, 16:00
7.275
-0.02
(-0.21%)
After-Hours: 20:00
Sage Therapeutics Research and Development Expense (Annual): 356.24M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 356.24M |
| December 31, 2022 | 326.16M |
| December 31, 2021 | 283.17M |
| December 31, 2020 | 292.71M |
| December 31, 2019 | 368.82M |
| December 31, 2018 | 282.11M |
| Date | Value |
|---|---|
| December 31, 2017 | 210.28M |
| December 31, 2016 | 120.76M |
| December 31, 2015 | 69.36M |
| December 31, 2014 | 24.10M |
| December 31, 2013 | 14.36M |
| December 31, 2012 | 7.229M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
283.17M
Minimum
2021
368.82M
Maximum
2019
325.42M
Average
326.16M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Biogen Inc | 2.462B |
| Outset Medical Inc | 57.31M |
| Biomarin Pharmaceutical Inc | 746.77M |
| Verastem Inc | 61.36M |
| Ardelyx Inc | 35.54M |